Jacquelyn Sumer
Compliance Officer at CULLINAN THERAPEUTICS, INC.
Net worth: 2 M $ as of 2024-03-30
Profile
Jacquelyn Sumer is currently working as the Secretary, Chief Legal & Compliance Officer at Cullinan Oncology, Inc. She previously worked as the Executive Director & Senior Corporate Counsel at Celgene Corp.
from 2017 to 2018.
She also worked as the Vice President & Assistant General Counsel at Bristol Myers Squibb Co. and as the Chief Legal & Compliance Officer at Genocea Biosciences, Inc. Ms. Sumer completed her undergraduate degree at Bucknell University and her graduate degree at Duke University School of Law.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CULLINAN ONCOLOGY, INC.
0.22% | 2024-02-21 | 94,133 ( 0.22% ) | 2 M $ | 2024-03-30 |
Jacquelyn Sumer active positions
| Companies | Position | Start |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Compliance Officer | 2022-08-14 |
Former positions of Jacquelyn Sumer
| Companies | Position | End |
|---|---|---|
| CELGENE | Director/Board Member | 2018-06-30 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
| GENOCEA BIOSCIENCES, INC. | Compliance Officer | - |
Training of Jacquelyn Sumer
| Bucknell University | Undergraduate Degree |
| Duke University School of Law | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| CULLINAN THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Stock Market
- Insiders
- Jacquelyn Sumer
